You are here

Article Text

Article menu
Download PDFPDF
Editorial
The positive predictive value of ct-proAVP (copeptin) in patients with STEMI
  1. Martin Möckel,
  2. Julia Searle
  1. Department of Cardiology and Division of Emergency Medicine, Charité—Universitätsmedizin Berlin, Berlin, Germany
  1. Correspondence to Professor Martin Möckel, Department of Cardiology and Division of Emergency Medicine, Charité—Universitätsmedizin Berlin, Campus Virchow Klinikum and Campus Charité Mitte, Augustenburger Platz 1, Berlin 13353, Germany; martin.moeckel{at}charite.de

https://doi.org/10.1136/heartjnl-2013-304217

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Recently Reinstadler et al reported on a study in n=54 patients diagnosed with STEMI who underwent copeptin sampling 2 (1–3) days after the index event and Cardiac Magnetic Resonance (CMR) on the same day. A follow-up CMR study was done after 4 months in n=47 patients.

    The authors found a strong and significant correlation between day 2 copeptin and ejection fraction, end systolic volume, stroke volume and per cent infarct mass. Additionally, using optimised cutoffs, adverse remodelling could be excluded by the combination of copeptin with NT-proBNP.1

    Copeptin is a stable glycopeptide comprising the C-terminal part of the AVP arginine-vasopressine prohormone.2 Copeptin is known to be released by the hypophysis early upon the trigger of arterial underfilling, for example, in the case of immediate …

    View Full Text

    Footnotes

    • Contributors MM drafted the manuscript; JS reviewed and edited the manuscript.

    • Competing interests None.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles